Advanced Enzyme Technologies reported a Q1 FY27 revenue of INR 189.8 Cr (+2% YoY, -7% QoQ), noting a INR 10 Cr sales reversal impact.

EBITDA came in at INR 51 Cr (-10% YoY) with 27% margins, and PAT at INR 38.6 Cr (-5% YoY). Management acknowledged a softer start due to lower realization, elevated energy costs, and a temporary sales mix shift.

However, they affirmed confidence in achieving double-digit revenue growth and 30-32% EBITDA margins for FY27. Key actions include a INR 69.7 Cr share buyback and 100% stake acquisition in JC Biotech for INR 7.979 Cr.

The US business is adapting with a branding focus, targeting 8-10% growth.

Overall, management is confident about progressive momentum as the year advances.